Neurocrine Biosciences, Inc.

    Jurisdiction
    United States
    LEI
    549300FECER0XBN49756
    ISIN
    US64125C1099 (NBIX)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    56 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €161.61 34.1% undervalued
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    7 / 7

    Profile

    Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Read full profile

    Fundamentals

    Net revenue
    €2.14B
    Gross margin
    98.5%
    EBIT
    €422.21M
    EBIT margin
    19.7%
    Net income
    €297.08M
    Net margin
    13.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €2.73B +27.7% €572.52M +92.7%
    €3.04B +11.3% €709.62M +23.9%
    €3.39B +11.3% €961.85M +35.5%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    GORMAN KEVIN CHARLES N/A -106K $126.41 -$13.44M

    Congress transactions

    Name Transaction date Value
    Lisa McClain August 13, 2025 $1.00K–$15.00K
    Lisa McClain August 13, 2025 $1.00K–$15.00K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 2.5M $276.80M +13K Buy
    George Soros 240K $26.52M +40K Buy
    Ray Dalio 87K $9.65M -245K Sell

    Earnings Calls

    Latest earnings call: October 31, 2023 (Q3 2023)

    Add to watchlist

    Notifications